Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kuo Wei Chan"'
Autor:
Xavier Pivot, Felicia Ang, Peggy Feyaerts, Martin Demarchi, Lisa Soyeon Park, Pierre Coliat, Jeong-Hyeon Lee, Michael Kim, Filip Deforce, Kristi Mclendon, Marie Paule Derde, Jocelyn hii, Kuo Wei Chan
Publikováno v:
Journal of Clinical Oncology. 38:579-579
579 Background: Trastuzumab, an approved prescription drug by EMA and FDA under the name Herceptin has become the key treatment in patients with HER2−positive breast cancer. HD201, developed by Prestige Biopharma Pte Ltd is a biosimilar candidate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26bcfcf116d9b571f7fc157f8aca4b70
https://doi.org/10.1200/jco.2020.38.15_suppl.579
https://doi.org/10.1200/jco.2020.38.15_suppl.579
Autor:
Pierre Coliat, Michael Kim, Xavier Pivot, Peggy Feyaerts, M. Benabdelghani, Martin Demarchi, Philippe Barthélémy, Lisa Soyeon Park, Marie Paule Derde, Kuo Wei Chan, Felicia Ang, Filip Deforce, Jocelyn hii, Roland Schott
Publikováno v:
Journal of Clinical Oncology. 38:e21556-e21556
e21556 Background: Prestige Biopharma Pte Ltd is developing HD204, a biosimilar candidate of Bevacizumab (Avastin). Bevacizumab has been approved in the treatment of a variety of metastatic tumours. Bevacizumab, a recombinant humanized monoclonal ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f668fab82644fef193baed6b036af6a
https://doi.org/10.1200/jco.2020.38.15_suppl.e21556
https://doi.org/10.1200/jco.2020.38.15_suppl.e21556
Autor:
Lisa Soyeon Park, Xavier Pivot, Jeong-Hyeon Lee, Michael Kim, Jocelyn hii, Felicia Ang, Kuo Wei Chan, Peggy Feyaerts
Publikováno v:
Journal of Clinical Oncology. 37:e12505-e12505
e12505 Background: Trastuzumab, an approved prescription drug by EMA and FDA under the name Herceptin has become the key treatment in patients with HER2 positive breast cancer. HD201, developed and owned by Prestige Biopharma Pte Ltd is a biosimilar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd68dfc83061b457c0ad5baed9dfc780
https://doi.org/10.1200/jco.2019.37.15_suppl.e12505
https://doi.org/10.1200/jco.2019.37.15_suppl.e12505
Autor:
Philippe Barthélémy, Xavier Pivot, Jocelyn hii, Martin Demarchi, Pierre Coliat, Michael Kim, Kuo Wei Chan, Peggy Feyaerts, Jeong-Hyeon Lee, Lisa Soyeon Park, Felicia Ang, Meher Ben Abdelghani
Publikováno v:
Journal of Clinical Oncology. 37:e15014-e15014
e15014 Background: Prestige Biopharma Pte Ltd is developing HD204, a biosimilar of the EU-approved and US-licensed Bevacizumab (Avastin) that is approved treatment for a variety of tumour types. Bevacizumab is a recombinant humanized monoclonal antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::910c39f2a6a92e36289e02d9207fd9e8
https://doi.org/10.1200/jco.2019.37.15_suppl.e15014
https://doi.org/10.1200/jco.2019.37.15_suppl.e15014